RxDoctor Payments Data

Cyprian Gardine, MD

Endocrinology, Diabetes & Metabolism · Grand Rapids, MINPI 1659583888

Payments from drug & device makers

$312in general payments, 2019–2025

Across 18 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$75
  • Pfizer$60
  • Novo Nordisk$41
  • Xeris Pharmaceuticals, Inc.$38
  • Companion Medical, Inc.$20
  • Medtronic$20
  • plus $59 from 4 others

What the payments were for

  • Food & beverage$25281%
  • Education$6019%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Dexcom, Inc.4$75
Pfizer3$60
Novo Nordisk3$41
Xeris Pharmaceuticals, Inc.2$38
Companion Medical, Inc.1$20
Medtronic1$20
Abbott1$18
AstraZeneca1$17
Lilly USA, LLC1$12
IBSA Pharma Inc.1$12

How this compares

$312 in reported general payments places this provider in the 25th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

See all endocrinology, diabetes & metabolism providers in Michigan

Medicare billing

Part B allowed, 2024
$41,609
Medicare patients
293
Services billed
681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide187$226,463
OzempicSemaglutide143$199,294
MounjaroTirzepatide148$194,336
JardianceEmpagliflozin134$171,693
FarxigaDapagliflozin Propanediol83$89,238
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog77$59,501
Bydureon BciseExenatide Microspheres30$48,997
Lantus SolostarInsulin Glargine,hum.Rec.Anlog194$43,769
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$43,074
Tresiba Flextouch U-200Insulin Degludec24$42,896
Humulin R U-500Insulin Regular, Human14$40,875
InvokanaCanagliflozin23$36,753
Humalog Kwikpen U-100Insulin Lispro92$34,833
Novolog FlexpenInsulin Aspart61$30,650
JanuviaSitagliptin Phosphate32$28,950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog$12$437,671378 claims
Novo NordiskOzempic, Novolog$41$208,089171 claims
AstraZenecaFarxiga$17$89,23883 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

Other endocrinology, diabetes & metabolism in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →